RARE - ウルトラジェニックス・ファ―マシュ―ティカル (Ultragenyx Pharmaceutical Inc.)

RAREのニュース

   Ultragenyx Pharmaceutical Must-See Earnings Estimates for: Stock market Insights & financial analysis  2021/02/11 14:47:00 Stock Market Daily
Ultragenyx Pharmaceutical announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Global Phenylketonuria (PKU) Treatment Market 2021:Drivers, Strategies, Segmentation, Application with Top Key Players-American Gene Technologies, Inc., Ultragenyx Pharmaceutical, Danone Nutricia , Reckitt Benckiser Group  2021/02/02 15:23:22 OpenPR
Global Phenylketonuria (PKU) Treatment Market is rising at substantial CAGR in the forecast period of 2019-2026. This rise in market can be attributed to increasing incidence rate of phenylketonuria, growing research in the field of genomics and biotechnology, increasing awareness
   Barclays Stick to Their Buy Rating for Ultragenyx Pharmaceutical By Investing.com  2021/01/11 01:25:13 Investing.com
Barclays Stick to Their Buy Rating for Ultragenyx Pharmaceutical
   Morgan Stanley Stick to Their Buy Rating for Ultragenyx Pharmaceutical  2020/12/16 20:31:49 Investing.com
Morgan Stanley Stick to Their Buy Rating for Ultragenyx Pharmaceutical
   Ultragenyx Pharmaceutical Inc. Sells 442,255 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock  2020/12/12 09:58:46 Watchlist News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Director Ultragenyx Pharmaceutical Inc. sold 442,255 shares of the stock in a transaction dated Tuesday, December 8th. The stock was sold at an average price of $105.54, for a total transaction of $46,675,592.70. Following the completion of the sale, the director now directly owns 2,557,745 shares in the company, valued […]
   Ultragenyx Pharmaceutical Must-See Earnings Estimates for: Stock market Insights & financial analysis  2021/02/11 14:47:00 Stock Market Daily
Ultragenyx Pharmaceutical announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Global Phenylketonuria (PKU) Treatment Market 2021:Drivers, Strategies, Segmentation, Application with Top Key Players-American Gene Technologies, Inc., Ultragenyx Pharmaceutical, Danone Nutricia , Reckitt Benckiser Group  2021/02/02 15:23:22 OpenPR
Global Phenylketonuria (PKU) Treatment Market is rising at substantial CAGR in the forecast period of 2019-2026. This rise in market can be attributed to increasing incidence rate of phenylketonuria, growing research in the field of genomics and biotechnology, increasing awareness
   Barclays Stick to Their Buy Rating for Ultragenyx Pharmaceutical By Investing.com  2021/01/11 01:25:13 Investing.com
Barclays Stick to Their Buy Rating for Ultragenyx Pharmaceutical
   Morgan Stanley Stick to Their Buy Rating for Ultragenyx Pharmaceutical  2020/12/16 20:31:49 Investing.com
Morgan Stanley Stick to Their Buy Rating for Ultragenyx Pharmaceutical
   Ultragenyx Pharmaceutical Inc. Sells 442,255 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock  2020/12/12 09:58:46 Watchlist News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Director Ultragenyx Pharmaceutical Inc. sold 442,255 shares of the stock in a transaction dated Tuesday, December 8th. The stock was sold at an average price of $105.54, for a total transaction of $46,675,592.70. Following the completion of the sale, the director now directly owns 2,557,745 shares in the company, valued […]
   Global Phenylketonuria (PKU) Treatment Market 2021:Drivers, Strategies, Segmentation, Application with Top Key Players-American Gene Technologies, Inc., Ultragenyx Pharmaceutical, Danone Nutricia , Reckitt Benckiser Group  2021/02/02 15:23:22 OpenPR
Global Phenylketonuria (PKU) Treatment Market is rising at substantial CAGR in the forecast period of 2019-2026. This rise in market can be attributed to increasing incidence rate of phenylketonuria, growing research in the field of genomics and biotechnology, increasing awareness
   Barclays Stick to Their Buy Rating for Ultragenyx Pharmaceutical By Investing.com  2021/01/11 01:25:13 Investing.com
Barclays Stick to Their Buy Rating for Ultragenyx Pharmaceutical
   Morgan Stanley Stick to Their Buy Rating for Ultragenyx Pharmaceutical  2020/12/16 20:31:49 Investing.com
Morgan Stanley Stick to Their Buy Rating for Ultragenyx Pharmaceutical
   Ultragenyx Pharmaceutical Inc. Sells 442,255 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock  2020/12/12 09:58:46 Watchlist News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Director Ultragenyx Pharmaceutical Inc. sold 442,255 shares of the stock in a transaction dated Tuesday, December 8th. The stock was sold at an average price of $105.54, for a total transaction of $46,675,592.70. Following the completion of the sale, the director now directly owns 2,557,745 shares in the company, valued […]
   Brokerages Anticipate Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to Post -$1.12 EPS  2020/11/18 15:58:43 Transcript Daily
Equities research analysts expect Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report earnings of ($1.12) per share for the current quarter, according to Zacks. Seven analysts have made estimates for Ultragenyx Pharmaceutical’s earnings, with the lowest EPS estimate coming in at ($1.39) and the highest estimate coming in at ($0.75). Ultragenyx Pharmaceutical posted earnings per share of […]

calendar